Beyond 2027, Idorsia aims to continue the sales trajectory of QUVIVIQ with a stable OPEX, leading to higher sustainable profitability. This could benefit from additional income from new collaborations ...

Among the generated designs included what Nabla claims to be “the first antibody activators ever reported” for CXCR7, a GPCR implicated in multiple cancers, thereby providing applications for ...

Researchers from Ileadbms Co. Ltd. presented the discovery and preclinical characterization of IL-21120033, a new CXCR7 agonist being developed for the treatment of inflammatory bowel disease.

ABSTRACT: The two known receptors, CXCR4 and CXCR7, for the chemokine stromal cell-derived factor-1 (SDF1) play a role in the development and metastasis of multiple cancers, including melanoma. CXCR4 ...

ABSTRACT: The two known receptors, CXCR4 and CXCR7, for the chemokine stromal cell-derived factor-1 (SDF1) play a role in the development and metastasis of multiple cancers, including melanoma. CXCR4 ...

DONGTAN, KOREA, February 13, 2025 - iLeadBMS, a spin-off biotech from Ildong Pharmaceutical Group, announced that it has received a notification from the US Food and Drug Administration (FDA) that its ...

Systemic sclerosis is an autoimmune disorder characterized by inflammation, vasculopathy and fibrosis, mainly affecting internal organs and the skin. There is still a lack of therapies for SSc-induced ...

IL1512 is an oral CXCR7 agonist and is classified as a first-in-class drug, a type of drug that has never been developed for the same therapeutic indication previously. Last month, iLeadBMS presented ...

CXCR7 is an atypical chemokine receptor that recruits β-arrestin (ARRB2) and internalizes into clathrin-coated intracellular vesicles where the complex acts as a scaffold for cytoplasmic kinase ...

ACKR3 (Atypical Chemokine Receptor 3), traditionally called CXCR7, is up-regulated in many cancers, including advanced prostate cancer, and represents promising targets for therapeutic intervention.

Platelet ACKR3/CXCR7 surface expression is increased and impacts prognosis in individuals with coronary artery disease (CAD), who have an atherothrombotic platelet lipidome. For a study, researchers ...

The work with Pfizer led to the publication of a paper on an orally bioavailable macrocycle modulator of the CXCR7 chemokine receptor, but Circle had a low profile by the standards of Big Pharma ...